Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diphenhydramine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.56 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | HTR2B | P41595 | 1/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diphenhydramine SCHEMBL28086272 | 1.00 | ADORA2B (0.62) | ADORA2BMAPK1ALDH1A1CYP1A2LMNA | |
| Diphenhydramine SCHEMBL6682222 | 1.00 | ADORA2B (0.62) | ADORA2BMAPK1ALDH1A1CYP1A2LMNA | |
| Diphenhydramine SCHEMBL4317477 | 1.00 | ADORA2B (0.62) | ADORA2BMAPK1ALDH1A1CYP1A2LMNA | |
| Benztropine SCHEMBL28142853 | 0.89 | ADORA2B (0.49) | ADORA2BMAPK1ALDH1A1CYP1A2LMNA | |
| Rizatriptan SCHEMBL17595763 | 0.80 | HTR1D (0.53) | ADORA2BMAPK1ALDH1A1CYP1A2LMNA | |
| Acefylline SCHEMBL308514 | 0.79 | ADORA2B (1.00) | ADORA2BMAPK1ALDH1A1LMNARXFP1 | |
| Acefylline SCHEMBL18191994 | 0.79 | ADORA2B (1.00) | ADORA2BMAPK1ALDH1A1LMNARXFP1 | |
| Acefylline SCHEMBL8402147 | 0.78 | ADORA2B (0.97) | ADORA2BMAPK1ALDH1A1LMNARXFP1 | |
| SCHEMBL10178001 | 0.76 | ADORA2B (0.70) | ADORA2BCYP1A2LMNAMAPTSMN1; SMN2 | |
| SCHEMBL10178196 | 0.75 | ADORA2B (0.68) | ADORA2BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2184 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230414702-A1 | COMPOUNDS AND PHARMACEUTICAL USE THEREOF IN THE TREATMENT OF CANCER | PEPKON SAS (FR) | 2023-12-28 | — | — | US | claimed |
| US-20200230128-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. | 2020-07-23 | — | — | US | claimed |
| US-10179109-B2 | Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates | CHARLESTON LABORATORIES, INC. (US) | 2019-01-15 | — | — | US | claimed |
| EP-3423041-A1 | PHARMACEUTICAL COMPOSITIONS | Charleston Laboratories, Inc. (US) | 2019-01-09 | — | — | EP | claimed |
| US-20180344728-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. | 2018-12-06 | — | — | US | claimed |
| WO-2018191584-A1 | NUTRITIONAL AND THERAPEUTIC SUPPLEMENT COMPOSITIONS | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-10-18 | — | — | WO | claimed |
| US-20170304327-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2017-10-26 | — | — | US | claimed |
| US-9789105-B2 | Pharmaceutical compositions | LOCL PHARMA, INC. (US) | 2017-10-17 | — | — | US | claimed |
| US-20170252302-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. | 2017-09-07 | — | — | US | claimed |
| CN-107072961-A | Pharmaceutical composition | 查尔斯顿实验室公司 | 2017-08-18 | — | — | CN | claimed |
| WO-2012116277-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. (US) | 2012-08-30 | — | — | WO | claimed |
| US-20120201888-A1 | Pharmaceutical Compositions | CHARLESTON LABORATORIES, INC. (US) | 2012-08-09 | — | — | US | claimed |
| EP-2240022-A2 | PHARMACEUTICAL COMPOSITIONS | Charleston Laboratories, Inc. (US) | 2010-10-20 | — | — | EP | claimed |
| WO-2009089494-A2 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. (US) | 2009-07-16 | — | — | WO | claimed |
| US-20090175939-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. (US) | 2009-07-09 | — | — | US | claimed |
| US-20050282879-A1 | Methods and composition for treatment of migraine and symptoms thereof | SALEHANI FOAD | 2005-12-22 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |